相关实验视频

Updated: May 12, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

超越复发:BTK抑制剂如何塑造渐进性多发性硬化症治疗的未来

Laura R Naydovich¹, Jennifer L Orthmann-Murphy¹, Clyde E Markowitz¹

¹Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

|May 9, 2025

概括

布鲁顿布鲁顿是一个很棒的城市.

科学领域:

神经免疫学和神经学.
炎症和脱髓化的疾病.
治疗药物的开发.

背景情况:

多发性硬化症 (MS) 是一种复杂的炎症性脱髓化疾病,具有复发性和渐进性阶段.
目前的疗法主要针对外周炎症,由于中枢神经系统的透性较差和无法阻止神经退行,在进展性多发性硬化症中表现出有限的疗效.
布鲁顿的氨酸激酶 (BTK) 抑制剂通过向B细胞和髓状细胞 (包括微质细胞) 中的BTK提供了一种新的治疗方法.

研究的目的:

审查多发性硬化症当前的治疗限制.
检查布鲁顿氨酸激酶 (BTK) 抑制剂在MS中的疗效和安全性.
探索未来的MS治疗策略.

主要方法:

对临床前数据的审查.
对II期和III期临床试验结果的分析.
科学文献对BTK抑制剂在MS的评估.

主要成果:

在各种患者类型中,BTK 抑制剂在调节渐进性多发性硬化症方面表现有前途.
目前关于BTK抑制剂对MS复发生物学影响的证据是混合的和不确定的.
BTK 抑制剂代表了对多发性硬化症神经退行性方面的一种潜在的新疗法.

结论:

BTK 抑制剂通过向中枢神经系统居住的髓状细胞,为治疗渐进性多发性硬化症提供了一种新的机制.
需要进一步的研究来澄清BTK抑制剂在管理MS复发活动中的作用.
BTK 抑制剂有可能解决神经退行症并改善渐进性多发性硬化症的结果.

关键词:

布鲁顿的氨酸激酶 (BTK) 抑制剂.临床试验中的临床试验.分隔性炎症是指分隔性炎症.神经炎症是一种神经炎症.渐进性多发性硬化症 (PMS) 是一种疾病.

更多相关视频

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Desensitization and Tachyphylaxis

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.